PBD Dimer Linkers Prevent Antibody Aggregation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers, despite their potential as antitumor agents, face challenges with poor bioavailability and protein aggregation when used in antibody-drug conjugates, particularly in water-based buffer solutions, limiting their therapeutic efficacy.
Innovation Solution
Development of novel PBD dimer derivatives that are linkable to cell surface binding ligands, allowing for conjugation without protein aggregation, enhancing bioavailability and therapeutic efficacy by facilitating targeted delivery to cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PBD dimers are used as cytotoxic agents in antibody-drug conjugates, then antitumor activity is enhanced, but protein aggregation occurs in water-based buffer solutions
Solution Approach 1:
The patent introduces a water-soluble linker as an intermediary component between the PBD dimer and the antibody. This linker acts as a mediator that prevents direct interaction between the hydrophobic PBD dimer and the aqueous environment, thereby preventing protein aggregation while maintaining the cytotoxic activity of the PBD dimer when conjugated to the antibody.
Solution Approach 2:
The patent modifies the chemical structure of the PBD dimer by changing parameters such as introducing water-soluble groups or modifying the linker chemistry. These parameter changes enhance the water solubility of the conjugate, preventing aggregation while preserving the DNA-binding and cytotoxic properties of the PBD dimer.
2Ease of operation
If PBD dimers are conjugated to cell binding agents, then targeted delivery to cancer cells is achieved, but bioavailability remains poor
Solution Approach 1:
The water-soluble linker serves as an intermediary that improves the bioavailability of the PBD dimer-antibody conjugate. By providing a hydrophilic interface between the PBD dimer and the aqueous physiological environment, the linker enhances the conjugate's stability and uptake by cancer cells while maintaining targeted delivery through the antibody's cell-binding properties.
3Strength
If conventional PBD dimers are used, then DNA binding affinity is high, but they cause significant protein aggregation in water-based media
Solution Approach 1:
The patent applies local quality modification by introducing water-soluble functional groups specifically at the linker region, while preserving the hydrophobic PBD dimer core that provides high DNA binding affinity. This localized modification allows the conjugate to maintain strong DNA binding capability while the water-soluble linker region prevents aggregation in aqueous environments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel PBD dimer derivatives effectively block cell proliferation and demonstrate improved antitumor activity when conjugated to cell binding agents, addressing the issues of bioavailability and aggregation, thereby enhancing their therapeutic potential for cancer treatment.
Implementation Method 1
These agents exert their antitumor antibiotics activity by the formation of a covalent adduct in the minor groove of a DNA with preference of a three base pairs of Pu-G-Pu (where Pu = purine; G = guanine) sequences, wherein their C11-position is electrophilic, enabling the molecules to alkylate the NH 2 group of a guanine in the minor groove of DNA
Implementation Method 2
The three carbon space ((n=3) C8/C8'-linked PBD dimer analog (DSB-120) covalently bind to a 5'-Pu-GATC-Py sequence by crosslinking opposite-strand guanines separately by 2 base pairs, span six DNA base pairs
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided are cytotoxic agents, pyrrolo[2,1-c][1,4]benzodiazepine (PBD) derivatives, their conjugates with a cell-binding agent, the preparation and the therapeutic uses in the targeted treatment of cancers, autoimmune disorders, and infectious diseases.